3 big pharma companies just reported earning – here's how they did it

An Eli Lilly & Co. logo is seen on a pill bottle sleeve on this arranged photo at a pharmacy in Princeton, Illinois.

Daniel Acker Bloomberg | Getty Images

Stocks of pharmaceutical giants Pfizer and Merck increased more than 1% in premarket trading on Tuesday after reporting quarterly results beating Wall Street expectations.

Shares of drug giant Eli Lilly fell 3.0% after releasing profit from the first quarter which increased profit expectations, but lost on revenue. Sales of two of Eli Lilly's drugs, Trulicity and Alimta, fell short of Wall Street's forecasts. Merck's earnings gained a slight boost from sales of vaccines during the worst outbreak of measles since the disease was eradicated from the United States and Keytruda's cancer immunotherapy drug.

Health care has been the worst stock market performer this year on concerns about drug price reform and "Medicare for All" proposals from democratic legislators. The SPDR Fund, an ETF that tracks healthcare's largest corporations, has risen by just 2.7% from Monday, which significantly slows down the broader market indices. The Dow Jones Industrial Average is up 1[ads1]3% in the same period, and S & P 500 is 17% higher.

Eli Lilly

Eli Lilly said it expects further price falls in the US this year, as well as increased competition from generics. The company's erectile dysfunction drug Cialis lost exclusivity last year.

The company now expects full-year revenue between $ 22 billion and $ 22.5 billion, lower than a previous forecast of $ 25.1 billion to $ 25.6 billion. However, it increased its adjusted full-year earnings forecast by 5 cents to $ 5.60 to $ 5.70 per share.


The reported earnings of $ 1.22 per share in the quarter, beating analysts' expectations of $ 1.06 per share. Revenue came in at $ 10.81 billion, beating estimates at $ 10.48 billion.

Merck raised his earnings guide for the year. It now expects a full-year adjusted earnings per share of between $ 4.67 and $ 4.79. That's higher than the previous forecast of $ 4.57 to $ 4.72.


Pfizer achieved 85 cents per share in the first quarter and beats Wall Street estimates by 10 cents. The company reported revenue of $ 13.12 billion, higher than the $ 12.99 billion forecast.

The New York-based drug company also increased earnings per share. Share with a percentage. It now expects between $ 2.83 and $ 2.93 per share.

For more on investing in healthcare innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21st.

Source link

Back to top button